G1 Therapeutics Raises $105M In IPO Guided By Mintz Levin
Stock in G1 Therapeutics Inc. debuted on Wednesday after the venture capital-backed clinical-stage cancer treatment research company priced a $105 million initial public offering under guidance from Mintz Levin Cohn Ferris...To view the full article, register now.
Already a subscriber? Click here to view full article